4 Clinical Trials for Pulmonary Fibrosis Treatment

Clinical Trials for Pulmonary Fibrosis TreatmentClinical Trials for Pulmonary Fibrosis Treatment

Clinical Trials for Pulmonary Fibrosis Treatment

Pulmonary fibrosis is a disease that affects the lung tissue by scarring it. Extensive damage to lung tissue causes inefficiency in transferring oxygen to different parts of the body. This leads to shortness of breath in the patient, even when they perform normal everyday tasks. Severe symptoms are seen for several days to even a few weeks. However, patients return to normal breathing once the acute exacerbation wears off.

Most cases of pulmonary fibrosis do not have a clear cause. Symptoms tend to become worse suddenly and dramatically in someone, while others may experience the symptoms worsening over a longer period of time. One of the key aspects that researchers are interested in are the major factors that worsen the condition of patients rapidly. Apart from this, research studies are also being conducted to find better diagnostic methods and improved treatment techniques to alleviate the symptoms of pulmonary fibrosis.

Top Clinical Trials for Pulmonary Fibrosis Treatment

This is our selection of the top clinical trials for pulmonary fibrosis treatment in 2021:

Top Clinical Trials for Pulmonary Fibrosis Treatment

Top Clinical Trials for Pulmonary Fibrosis Treatment

1 – Treating People with Idiopathic Pulmonary Fibrosis with the Additional of Lansoprazole (TIPAL)

Idiopathic Pulmonary Fibrosis (IPF) causes progressive scarring to the lung tissue and results in coughing and breathlessness. Patients suffering from IPF also exhibit reflux disease symptoms which cause stomach acid to enter into the lungs and damaging them potentially. As Proton Pump Inhibitors (PPIs) have been effective in stopping stomach acid production, the research is focused on finding its effectiveness to reduce reflux symptoms, such as heartburn and reducing IPF progression.

This clinical study aims to research if IPF develops slower when treated with PPIs. The results of this study will determine whether PPIs should be recommended for IPF patients.

  • Study Type – Interventional (Clinical Trial)
  • Enrolment – 298 participants
  • Allocation – Randomized
  • Primary Purpose – Treatment

2 – Study of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis (IPF)

This study is being conducted to determine the difference in baseline changes with Six Minute Walking Distance (6MWD) when pulmonary rehabilitation (PR) is included to a stable underlying nintedanib therapy in patients suffering from idiopathic pulmonary fibrosis (IPF). The research is also focused on determining the difference in changes in Quality of Life (QoL) when pulmonary rehabilitation is included in stable underlying nintedanib therapy in patients suffering from IPF. Another aim of this clinical trial is to decide if an enduring effect of 6MWD, QoL and lung function from pulmonary rehabilitation when PR technique is used in stable underlying nintedanib therapy in patients with idiopathic pulmonary fibrosis (IPF).

  • Study Type – Interventional (Clinical Trial)
  • Enrolment – 19 participants
  • Allocation – Randomized
  • Primary Purpose – Treatment

3 – Mineralocorticoid Receptor Antagonist and Pulmonary Fibrosis in COVID-19 (SpiroCOVID19)

The SARS 2019 CoV-2 virus causes an acute infection of the lower respiratory tract. Since it was discovered in 2019, scientists from all over the world have been focusing on finding the right treatment and a vaccine for this disease. Around 80% of COVID-19 patients are asymptomatic yet many develop respiratory failure which causes complications that often result in death. Pulmonary fibrosis is one such complication that is seen rising with the onset of COVID-19 and it can cause prolonged disability due to breathing problems.

This study is focused on evaluating the efficacy of intravenous forms of mineralocorticoid receptor antagonist cenrenoate potassium in the treatment of COVID-19 associated pulmonary fibrosis, using the immune system mechanism.

  • Study Type – Interventional (Clinical Trial)
  • Enrolment – 50 participants
  • Allocation – Randomized
  • Primary Purpose – Treatment

4 – Colchicine and Post COVID-19 Pulmonary Fibrosis

Pulmonary fibrosis often develops into adult respiratory distress syndrome (ARDS). Around 40% of COVID-19 patients develop ARDS, of which around 20% of cases are severe. Radiographic, clinical and autopsy reports of pulmonary fibrosis are normal following a COVID-19 infection. The existing evidence suggests that pulmonary fibrosis can complicate the COVID-19 infection. Colchicine is an effective anti-inflammatory drug that inhibits the synthesis of tumor necrosis factor-alpha and IL-6, monocyte migration, along secretion of matrix metalloproteinase-9. This subdues cytokinesis and chemokinesis secretion as well as aggregation of in vitro platelet.

  • Study Type – Interventional (Clinical Trial)
  • Enrolment – 250 participants
  • Allocation – Randomized
  • Primary Purpose – Treatment

Conclusion

Numerous research studies are conducted every year worldwide to discover new and innovative treatment methods for severe respiratory disorders, such as pulmonary fibrosis. By participating in these clinical trials, you can contribute to the discovery of effective and efficient pulmonary fibrosis treatment methods.

See Also

Tooth Regeneration Clinical Trials

Where to find paid clinical trials for smokers

Types of Weight Loss Surgery Procedures

Reference links:-

https://www.pulmonaryfibrosis.org/patients-caregivers/medical-and-support-resources/clinical-trials-education-center

https://policylab.us/clinical-trials/pulmonary-fibrosis/

https://clinicaltrials.gov/ct2/show/NCT04912011?recrs=a

https://clinicaltrials.gov/ct2/show/NCT04818489?recrs=a

https://clinicaltrials.gov/ct2/show/NCT04965298?recrs=a

https://clinicaltrials.gov/ct2/show/NCT03717012

Got Questions? Ask us @medical_grants

Leave a comment

Your email address will not be published.


*